Climatotherapy at the Dead Sea is a remittive therapy for psoriasis: combined effects on epidermal and immunologic activation.

Authors: Hodak E , Gottlieb AB , Segal T , Politi Y , Maron L , Sulkes J , David M
Affiliations:
Source: J Am Acad Dermatol. 2003 Sep;49(3):451-7.
DOI: 10.1067/S0190-9622(03)00916-2 Publication date: 2003 Sep E-Publication date: Not specified Availability: abstract Copyright: © 2003 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.
Language: English Countries: Not specified Location: Not specified Correspondence address: Emmilia Hodak, MD, Department of Dermatology, Rabin Medical Center, Beilinson Campus, Petah Tiqva 49 100, Israel.
Email : ehodak@clalit.org.il

Keywords

Article abstract

BACKGROUND:

The beneficial effect of climatotherapy at the Dead Sea (CDS) for psoriasis has been established clinically but there is a striking lack of studies assessing its in vivo effect at the molecular and cellular levels.

OBJECTIVE:

We sought to study the response of activated immunologic cells and keratinocytes in psoriatic lesions to CDS.

METHODS:

A total of 27 patients with chronic, stable, plaque-type psoriasis treated with CDS for 28 consecutive days were evaluated with the Psoriasis Area and Severity Index score and quantitative histologic measures.

RESULTS:

After 4 weeks of treatment, the overall Psoriasis Area and Severity Index score decreased by 81.5%. Complete clearance was achieved in 48% of the patients, and moderate to marked improvement in 41%. The average duration of remission was 3.3 months. Histologically, there was an overall reduction in malpighian layer thickness by 63.4%, and keratinocyte hyperplasia, assessed by Ki-67 cell cycle antigen expression, decreased by 78%; residual cell proliferation was confined mainly to the basal layer. These changes were accompanied by normalization of keratin 16 expression in 90% of the patients. T lymphocytes were almost totally eliminated from the epidermis (depletion of >90% of CD3(+) and CD25(+) cells), with only a low number remaining in the dermis (depletion of 69.4% of CD3(+) cells and 77.4% of CD25(+) cells). This reduction in activated T cells was accompanied by a marked reduction in HLA-DR expression by epidermal keratinocytes.

CONCLUSIONS:

CDS is a highly effective and remittive treatment for moderate to severe plaque-type psoriasis, leading to a reversal of both pathologic epidermal and immunologic activation.

Find it online